BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37165308)

  • 1. JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.
    Cai X; Duan X; Tang T; Cui S; Wu T
    BMC Cancer; 2023 May; 23(1):423. PubMed ID: 37165308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.
    Vetter NS; Kolb EA; Mills CC; Sampson VB
    Mol Cancer Res; 2017 Jul; 15(7):953-964. PubMed ID: 28275089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.
    Chakravarthi BVSK; Chandrashekar DS; Agarwal S; Balasubramanya SAH; Pathi SS; Goswami MT; Jing X; Wang R; Mehra R; Asangani IA; Chinnaiyan AM; Manne U; Sonpavde G; Netto GJ; Gordetsky J; Varambally S
    Mol Cancer Res; 2018 Jul; 16(7):1125-1137. PubMed ID: 29025958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound-Induced Microbubble Cavitation Combined with miR-34a-Loaded Nanoparticles for the Treatment of Castration-Resistant Prostate Cancer.
    Wang Z; Chen C; Tao Y; Zou P; Gao F; Jia C; Liu L; Li G; Zhang G; Duan Y; Shi Q
    J Biomed Nanotechnol; 2021 Jan; 17(1):78-89. PubMed ID: 33653498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GR silencing impedes the progression of castration-resistant prostate cancer through the JAG1/NOTCH2 pathway via up-regulation of microRNA-143-3p.
    Zhang L; Jiang H; Zhang Y; Wang C; Xia X; Sun Y
    Cancer Biomark; 2020; 28(4):483-497. PubMed ID: 32568179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
    Nakagawa T; Sato Y; Tanahashi T; Mitsui Y; Kida Y; Fujino Y; Hirata M; Kitamura S; Miyamoto H; Okamoto K; Muguruma N; Bando Y; Takayama T
    Gastric Cancer; 2020 May; 23(3):426-436. PubMed ID: 31677131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
    You B; Zhang KC
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
    Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
    Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
    Zhang J; Li Q; Zhang S; Xu Q; Wang T
    Exp Cell Res; 2016 Nov; 349(1):77-84. PubMed ID: 27743893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
    Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
    Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
    Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
    Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
    Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
    Xu W; Jiang K; Shen M; Chen Y; Huang HY
    Oncol Rep; 2016 Jan; 35(1):352-8. PubMed ID: 26498874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR‑491‑5p.
    Li Y; Wang Y; Xie Z; Hu H
    Mol Med Rep; 2019 Apr; 19(4):2489-2496. PubMed ID: 30720092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.
    Cao H; Wang D; Sun P; Chen L; Feng Y; Gao R
    Aging (Albany NY); 2021 Oct; 13(19):23096-23107. PubMed ID: 34613933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.